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Background: The use of medical stimulants to sustain attention, augment memory and enhance intellectual
capacity is increasing in society. The use of Methylphenidate for cognitive enhancement is a subject that has
received much attention in the literature and academic circles in recent times globally. Medical doctors and
medical students appear to be equally involved in the off-label use of Methylphenidate. This presents a potential
harm to society and the individual as the long-term side effect profile of this medication is unknown.
Discussion: The implication of the use of Methylphenidate by medical students and doctors has not been fully
explored. This article considers the impact of this use on the traditional role of medicine, society, the patient and
suggests a way forward. We discuss the salient philosophy surrounding the use of cognitive enhancement. We
query whether there are cognitive benefits to the use of Methylphenidate in healthy students and doctors and
whether these benefits would outweigh the risks in taking the medication. Could these benefits lead to tangible
outcomes for society and could the off label-use of Methylphenidate potentially undermine the medical profession
and the treatment of patients? If cognitive benefits are proven then doctors may be coerced explicitly or implicitly
to use the drug which may undermine their autonomy. The increased appeal of cognitive enhancement challenges
the traditional role of medicine in society, and calls into question the role of a virtuous life as a contributing factor
for achievement. In countries with vast economic disparity such as South Africa an enhancement of personal utility
that can be bought may lead to greater inequities.
Summary: Under the status quo the distribution of methylphenidate is unjust. Regulatory governmental policy must
seek to remedy this while minimising the potential for competitive advantage for the enhanced. Public debate on the
use of cognitive enhancement is long overdue and must be stimulated. The use of Methylphenidate for cognitive
enhancement is philosophically defendable if long-term research can prove that the risks are negligible and
the outcomes tangible.
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Methylphenidate (Ritalin, Concerta) has been used since
1960 for treating children and adults suffering from
attention deficit hyperactivity disorder (ADHD). It acts
by delaying the reuptake of the neurotransmitters nor-
adrenaline and dopamine, which prolongs their bio-
chemical effects in the central nervous system. This has
been shown to result in an increase in attention and a* Correspondence: beyer@sun.ac.za
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unless otherwise stated.decrease in restlessness in children and adults who have
been diagnosed with ADHD [1]. It has also been proven to
significantly improve the ability to stay awake in patients
suffering from sleeping disorders such as narcolepsy [2].
Perhaps desiring similar effects, the prevalence of Methyl-
phenidate usage for non-medical cognitive enhancement
purposes by students and academics alike is increasing on
university campuses worldwide [3,4]. Medical campuses
appear to be no different. After graduating high school in
South Africa prospective medical students enter a 6 year
degree of MB, ChB (Bachelors in Medicine, Bachelors in
Surgery) followed by two years of internship and one yeartd. This is an Open Access article distributed under the terms of the Creative
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Health Professions Council of South Africa as medical
practitioners. The two years of internship and one year of
community service are often done in rural settings, where
the patient to doctor ratio is high. Arguably with the
duration and intensity of the coursework and the long
hours expected of medical students and interns within
South Africa, the levels of illicit use may even be higher
[5]. While the benefits of Methylphenidate in patients
suffering from attention deficit disorders have been
tested and proven, the benefits for a healthy person cannot
be assured. There are a number of concerning studies
that have emerged recently which illuminate the needs for
long-term prospective studies on the use of methylphenid-
ate amongst the healthy, as well as public discourse on
cognitive enhancers in general and methylphenidate in
particular. These studies suggest that the use of methyl-
phenidate by the healthy may result in a cognitive trade
off of enhancement of executive function in novel tasks
with impairment of previously established performance.
Additional studies have supported this idea, showing
that although healthy users of methylphenidate may
perceive an increase in current aptitude, they may actu-
ally be losing their general aptitude. Furthermore, in
sleep-deprived individuals treated with Methylphenid-
ate, results have shown that people overestimated their
own performance, and experienced a subjective sensa-
tion of stimulation with only a mediocre improvement
in attention. The perception of methylphenidate as an
effective cognitive enhancer may be more related to the
subjective effects experienced by the user than its realistic
implications. This subjectivity contributes to the common
human tendency of overestimating new technologies in
the discussion of their benefits and risks [6]. As medical
practitioners, it is of utmost importance to use evidence
-based medicine to inform best clinical practice, hence it
would be incorrect to extrapolate the effects of Methyl-
phenidate for the healthy from the evidence that stands
for those with medical indications [7]. The evidence of the
effect of Methylphenidate on healthy people is lacking, not
just quantitatively, but in reliability. The latter is mostly
due to the relative lack of comparative baseline variables
being tested, such as not attempting to, or not being able
to quantify the baselines for intelligence, wakefulness or
cognitive ability in the subjects tested. Furthermore, of
the available studies, the majority are single dose studies,
although it has been shown that Methylphenidate follows
dose dependent nonlinear kinetics in narcoleptic and
healthy patients [8]. This means that the effects of an
increase in dose cannot be accurately predicted on the
basis of a single dose study. As a large number of the
studies of Methylphenidate’s efficacy and therapeutic
safety profile have been conducted on children, the safety
and efficacy of Methylphenidate may vary in unforeseenways between adult medical students, practitioners and
the children on whom these studies were conducted. It is
therefore critically important to acquire further evidence
regarding the quantified and dose dependent effects on
differing groups of healthy patients before any decision
can be made. It is time for ‘medicine, healthcare and
society to prepare for broader and more prevalent non-
medical uses of pharmaceuticals’ [3] and to debate all
the implications thereof.
Discussion
Methylphenidate: efficacy and adverse effects
Systematic review has shown that the expected effects
of methylphenidate exceed its actual effects, as demon-
strated in single or double-blind randomised controlled
trials [9]. A single dose of methylphenidate has been
shown to benefit memory in healthy subjects, as well as
increase subjective ratings for interest, excitement and
motivation in a mathematical task. This effect was not
found in passive tasks. Indeed there is evidence that
usage of these substances by patients without an attention
deficit disorder may result in a cognitive trade off [7] by
increasing their short term memory at the expense of their
long term memory. The perception of Methylphenidate
as a major drug of enhancement may be more closely
linked with the association of educational success in
school children. The idea of this association leads to
the suggestion of the potential for an enhanced level of
cognitive functioning in the healthy. However, educational
success is better understood as being attributed to multiple
factors [10]. This presents a confounding factor in neuro-
psychological research, in that a person’s performance
in research tests is influenced by more than one cogni-
tive process, since these processes are not isolated, but
rather work together and are interrelated [11]. This
interwoven nature of cognition renders it difficult to
assess specific avenues of cognitive enhancement by
only considering the efficacy of a person performing
novel cognitive tasks.
Unlike a drug intended to cure or remedy a condition;
wherein the efficacy can be quantified on inhibition of an
organism (in terms of antibiotics) or improvement to a
normal level of functioning (in terms of antipsychotics),
the testing of whether Methylphenidate adds to an already
functional person’s utility may be difficult to quantify.
How would a researcher be able to adequately assess
the varying baselines of functionality and the relative
subjectivity of human traits like intelligence, concentration
and aptitude? Perhaps concentration could be shown to
be qualitatively enhanced. However, at what level of
qualitative analysis would we find sufficient evidence to
deem the drug effective and more so than conventional
means of concentration and wakefulness enhancement,
such as a good night’s sleep or a strong cup of coffee?
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the studies conducted on Methylphenidate use in the
healthy, for we cannot correlate Methylphenidate use
and any cognitive outcome on the user without all of
these co-founding variables being accounted for.
The role of medicine in cognitive enhancement
The conventional role of medical intervention is that of
curing illness and restoring the patient to a functional or
‘normal’ level. Further consideration would be necessary as
to whether utilitarian ethics justifies or vilifies supporting
research into medications intended to enhance the human
condition, rather than medications which support this
conventional role of medical intervention. Perhaps it could
be argued that an enhancement of perceived aptitude
would aid in mental wellbeing, but medical practitioners
need to be wary of walking the tenuous line between
treating real illness and over treating perceived inad-
equacy. The usage or advocation for usage of cognitive
enhancement medication may necessitate a re-evaluation
of the role of medicine in society. However, it can be
argued that the concept of Methylphenidate as an en-
hancer does not represent a challenge to the historical
view of the role of medicine. The use of, for example,
laser surgery to correct visual abnormalities often returns
the person to a level of vision that is greater than their
baseline and enhancement is used and advocated for on a
widespread basis when we take vaccines to prepare our
immune response against certain infectious diseases [12].
Therefore the correlation between illness and intervention
may never have been as clear. Perhaps enhancement is
more congruent than incompatible with the current role
of medicine in society.
The widespread use of Methylphenidate for enhance-
ment purposes requires a scrutiny of the cost-benefit
analysis of medical intervention for the patient. Medical
intervention is usually justified by the analysis of the
utility lost under a medical condition justifying the pos-
sible adverse effects of that intervention. This is why a
patient suffering from cancer may be justifiably treated
with radiation therapy, although the adverse effects may
be appreciable. However, a medical practitioner would
find it difficult to justify such a radical intervention for a
less fatal condition. This analysis is particularly relevant
for Methylphenidate, as the identified side effects may
not be acceptable or ethically justifiable for a patient
who does not have a condition that justifies them. Some
of the most frequently encountered side effects are a
decreased appetite, dry mouth, sleeping problems, mild
forms of depression and repetitive movements (tics) [13].
More dangerous side effects associated with Methylphenid-
ate use involve an exacerbation of predisposed conditions
such as anxiety disorders or of pre-existing conditions such
as cardiac arrhythmias and glaucoma. These major sideeffects and contra-indications for Methylphenidate usage
maybe ameliorated if a medical practitioner thoroughly
investigates his/her patient and rules out dangerous
physiological predispositions before prescribing the drug.
Furthermore, continuous monitoring and the scheduling
of Methylphenidate may assist in preventing and detecting
cases of addiction, this would act to ameliorate the possi-
bility that Methylphenidate even in the prescribed oral
form, may have large abuse potential [14]. However, it is
important to note that the use of Methylphenidate has
been implicated in lowering, not elevating, the chance
of future abuse of stimulants [15]. Very little is known
about long term use in the healthy, and the widespread
neurochemical systems implicated in the use of Methyl-
phenidate suggest that in addition to cognition they
may impact emotional and motivational functions [16].
A further risk is that serious side effects like cardiac
arrhythmias have a higher likelihood amongst older
people with incipient cardiovascular disease and that
this group of people and older doctors are increasingly
likely to use the drug to stave off the fraying of their
cognitive ability [17].
Under the status quo, wherein people acquire Methyl-
phenidate either from a colleague or another illicit source,
these risks predispose them to unforeseen and potentially
fatal side effects [1]. This presents a far greater risk to
the public compared to scheduled, controlled, medically
moderated distribution of the medication. It is true that
Methylphenidate has been declared safe enough for wide-
spread use in children and young people with ADHD
for a long period of time. As ADHD is not life-threatening,
an analogy may be drawn with the benefits of therapeutic
intervention being similar to those of enhancement inter-
vention. The same benefits would seemingly justify its
use from a safety perspective as well, as the adults using
Methylphenidate for enhancement purposes likely value
these effects as much as those with ADHD. In addition to
this, Methylphenidate has been proved to have a low
enough risk profile to be ethical for use in research to test
cognitive effects in healthy subjects, where the effect is
clearly more elective than therapeutic [18]. The societal
sense of unease with cognitive enhancement could be
seen as analogous to the early stages in the development
of cosmetic surgery. What was, for a time, seen as the
patient irrationally accepting a large risk for what was
perceived to be a small, unnecessary benefit, has grown
to be a relatively accepted form of self-augmentation,
which increases the general happiness of the patient,
inherently a good thing. Furthermore the history of
cosmetic surgery shows that many medical practitioners,
given the right evidence and cultural frameworks, may
become comfortable with non-therapeutic interventions
[19]. Cognitive enhancement medication may follow a
similar path [20].
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The fields of philosophy and bioethics surrounding cog-
nitive enhancement have provided many debates and
differing stances [17,18,21]. The intention in this section
is to summarise the salient points of cognitive enhance-
ment in general, and then to analyse how these points
tie in with the idea of medical students and doctors
using Methylphenidate.
The arguments surrounding augmenting the human
condition draw a strong analogy with the ethical debates
surrounding gene doping in sport. This involves the use
of biochemistry to alter the expression of certain genetic
sequences in human genotypes leading to the expression
of desirable, or inhibition of undesirable, cells or human
genes to improve athletic performance. The primary argu-
ment against this is that it presents an actual or potential
health risk to the athlete [22] which ties strongly with
the medical principle of primum non nocere (first do no
harm). The second argument against genetic doping is
that it violates the spirit of sport in lieu of the princi-
ples of ethics, honesty and respect for rules governing
the profession [22]. These values, although tenuous in
sport, are certainly applicable in the medical profession.
There is, however, far less consensus on what constitutes
cheating in a medical environment. If Methylphenidate
usage amongst the healthy does provide practical benefits
for the user and these benefits actively translate into
tangible outcomes then it is easy to consider the example
of a medical student who may achieve better marks, and
potentially pursue a more competitive speciality by using
Methylphenidate to gain a competitive advantage over
their peers [23]. In this example there is a demonstrable
harm upon the unaugmented students, as they have been
placed at a comparative disadvantage in what could be
argued to be an unfair manner.
The lack of consensus on what constitutes cheating
becomes more prominently an issue for the sporting
analogy when dealing with cognitive enhancement amongst
medical doctors and researchers. In contrast to the above
scenario wherein a medical student may take the drug
explicitly for personal academic success, it may be de-
fensible to have our top medical researchers on cogni-
tive enhancement drugs [24]. This is because research
can be viewed as a non-zero sum game, wherein the
potential achievements of an individual or group, such
as the discovery of a cure for a disease such as HIV
would surely benefit humankind far more than the
individual doctor or academic. Another example is if
an augmented doctor is able to concentrate to a greater
extent on their patient and be more conscientious, it
would likely lead to a greater outcome for the patient. In
these two scenarios the benefits to the immediate doctors
or researchers, and perhaps their comparative advantage
over their colleagues [25], is not the only, or the mostrelevant, factor. The primary aim of the medical field
should aim to do what is best for the patient and with
this analysis any competitive advantage over colleagues
appears to be more of a secondary outcome.
There is a further consideration in this calculation,
that in improving relative inequalities and enhancing
personal competencies we may begin to undermine the
ability of the population at large to identify with the
human characteristics of these athletes and academics.
This may lead to their achievements being considered
products of science rather than of human endeavour.
This would invalidate the correlation with hard work,
character, effort and achievement [26] which is one of the
reasons why, for many years, cognitive enhancement has
been considered incompatible with virtue ethics.
The pursuit of the good life is considered to be the
pursuit of a virtuous life. This has led to the criticism of
virtue ethics as being too demanding and thus obtain-
able only by an elite group of people [27]. This criticism
has received support by studies in the behavioural sciences,
which suggest that humans are cognitive constrained.
Examples of these constraints are the findings that suggest
humans are particularly bad at deferring judgement and
making accurate decisions based on information given [28].
This undermines the pursuit of a good life in virtue ethics
as normative theories are largely based on intuitions.
Joshua Green published a study in 2001 analysing what
parts of the brain are involved in specific ethical reason-
ing [29]. He found that “deontological moral judgements
are primarily driven by automatic emotional responses”.
Furthermore, the stability of our judgements has also
been found to be prone to manipulation through a vast
array of methods, from hypnosis to transcranial magnetic
stimulation. These findings, in collaboration with those
previously discussed may suggest that the failings of the
majority in the pursuit of eudaimonia are due to biological
factors more so than inadequate training or motivation
[27]. This renders the majority of people unable to achieve
a good life due to factors beyond their control. Perhaps
more importantly these findings also suggest that the way
a person deals with moral dilemmas may be biologically
constrained, open to manipulation and unreliable [30].
Recent articles have suggested that the use of cognitive
enhancement as a facilitator, in adjunction with moral
and epistemic virtues, may make the pursuit of a virtuous
life, with morally responsible judgements, more achievable
[31]. It is especially important to incorporate these virtues,
as without them there can be no suggestion that cognitive
enhancement would translate to moral goodness. This
analysis is particularly important in the context of this
article, as doctors, perhaps more so than other people,
are ultimately reliant on the pursuit of a virtuous life. If
cognitive enhancement helps to facilitate this it would
certainly be an attractive outcome.
Beyer et al. BMC Medical Ethics 2014, 15:20 Page 5 of 8
http://www.biomedcentral.com/1472-6939/15/20If we could ascertain that the use of Methylphenidate
creates more effective doctors, the benefits to society are
relatively self-evident. Furthermore, if this increased utility
correlated to an acceleration of medical breakthroughs, and
a potential increase in collective happiness, then this would
satisfy Jeremy Bentham’s consequentialist basis for his Utili-
tarian moral philosophy [32], which states that the moral
outcome is the one which leads to the greatest good for the
greatest number. Opponents of this utilitarian approach to
cognitive enhancement often take a deontological defence
arguing that the act of using a drug to enhance your per-
sonal cognition may be hedonistic and thus not justifiable.
However, Kant also argued that the categorical imperative
could be interpreted through reason alone to delineate
what inviolable rights are [33]. If we accept that the inher-
ently inviolable right in this debate is that of the right to
enhance personal utility then attempts to achieve that en-
hancement could be justifiable, regardless of an increase
or a decrease in personal utility or societal benefit or detri-
ment as an outcome, so long as the usage is duty driven.
The latter part of this argument is an important one,
and requires comprehensive review by governmental
bodies to prevent exploitation, either by the person who
argues personal utility for societal benefit, or the society
that may implicitly coerce such a person into pursuing
this potential collective benefit at expense of their own
autonomy. Rawls’ ‘veil of ignorance’ expansion places upon
us an imperative to equalise distribution of resources to
lessen our own risk of being born into oppression [34].
Avoiding potential exploitation may seem to invalidate
the usage of Methylphenidate under a scenario of unfair
advantage; however Rawls argued that we may accept
unequal distributions under one condition: the inequality
must be to the benefit of those who are the worst off
[34]. Inequality in potential achievement for the sake of
innovation and societal advancement may pass this
analysis and satisfy the Rawlsian difference principle.
The salient point is that under the status quo the distri-
bution of Methylphenidate for cognitive enhancement is,
by the principle of equal liberty, unjust. Access to, and
usage of, this drug amongst the healthy is restricted to a
privileged class of people who are able to acquire it through
their own personal, financial or social resources. This un-
regulated distribution further entrenches social inequality
within a society, by restricting access for the less privileged
and with no solid governmental policy moderating the
access for the privileged. The following section will further
advance the case for, and discuss the steps to implement,
such a policy, while considering the implications thereof.
The implications of, and policy for, allowing for
moderated cognitive enhancement
If we extend the harms and risks inherent in the currently
unregulated system of cognitive enhancement medicationsto a system when cognitive enhancement is endorsed,
but remains unregulated [35], then there are various
role-players we need to exam. Firstly, the individuals
within society may be explicitly or implicitly coerced
into using these medications due to utility calculations
of corporate entities [36]. For example, a transport
company, which is able to coerce their drivers to take
medications to enhance wakefulness and concentration,
would be in a position to transport goods further, with
fewer stops, and thus be in a position to make a larger
profit, than their competitors. This would give them a
competitive advantage in their industry and their com-
petitors would either have to adopt the same policy or
face the prospect of being driven out of business. It
may be an idealistic view that the medical community
would be exempt from being drawn into methods of
productivity enhancement.
This argument could be made with private medical
facilities, having fewer doctors working longer hours
during a call rotation would provide a profit motive for
coercion by the administrators of these facilities [37].
Also, in many parts of the world the incentive [38] or
requirement for doctors to work overtime in the medical
sector is immense [39]. Coffee and energy drinks may
make way for more effective methods of concentration
and wakefulness enhancement. The principles of personal
autonomy tend to support the idea that societal interfer-
ence in these scenarios needs to be adequately justified lest
it be deemed paternalistic, arbitrary and not legitimate.
However, in an absolutely unregulated environment, as
described above, the potential for coercion may violate
the autonomy and rights to equality of the average, as
choosing to not, or not being in a position to, enhance
may put you at a competitive disadvantage [40]. This is
because if we are to accept an inherent advantage provided
by access to and usage of these drugs we may logically
extend this advantage to an increase in employability
for the augmented over the drug free.
In this way, if cognitive enhancement becomes only a
pursuit of private persons and businesses, the public sector
and the worse off may become less competitive. This is an
especially relevant danger in South Africa where inequality
in access to pharmaceuticals is drawn along an economic,
and historically, a racial divide. This may lead to perpetu-
ation of the economic divide, making the poor and previ-
ously disadvantaged even less able to gain employment and
develop skills [41].
This calls for government to adopt an active policy to
offset these potential harms, and allow equitable distri-
bution of these resources in a society, or minimise the
comparative advantage they provide. The former would
require the development of generics and government
subsidisation, increasing the availability of these drugs for
the historically less privileged, an approach that would
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sources in a medical setting would suggest that only after
all legitimate medical concerns are adequately addressed
within a population may state financing of enhancement
medication be permissible. This approach, therefore, seems
economically unfeasible.
Fortunately, when it comes to democratic societies,
the state does not have to decide to either subsidise the
development of, or illegalise a substance. They may act
to curtail the use of these potentially hazardous drugs,
whilst maintaining the autonomy of the individual, and
promoting equitable distribution of resources. This is
premise for the policy we will advocate for. This policy
would include disincentivising people from using these
drugs by educating the population on their realistic
effects and relatively unknown side effect profile; while
discouraging their usage by taxation included in the
price of sale, as currently legal risky behaviour [35], like
tobacco, is currently taxed.
The funds gained by the personal taxation of Methyl-
phenidate could be allocated to the medical care of the
most disadvantaged in society as well as the develop-
ment of affordable generics when the long-term effects
of these medications are known. An additional corporate
tax on businesses whose employees use these medications
would serve two purposes. Firstly it would increase the
cost and therefore minimise the profit incentive of
businesses coercing their employees into using these
drugs, ameliorating this risk to personal autonomy.
Secondly this new revenue stream for the state could
be invested into the research on orphan disease, which
are diseases that are so rare that there is no motive for
private pharmaceutical companies to develop treatments
for them. With this increased revenue the state could
pursue this research [36].
If cognitive enhancement may be considered a new
technology with potentially hazardous effects for those
engaging in it, the state may require users to prove
adequate knowledge of the enhancer by passing a test and
acquiring a license, allowing for the capacity of informed
consent. Furthermore, those that acquire this license could
be compelled to acquire additional, appropriate medical
insurance, to lessen the potential burden on the state. The
people who are licensed for the use of these cognitive en-
hancers could be compelled to participate in a prospective
cohort study on the long-term effects of these cognitive
enhancers. Although the state may maintain their position
on the potentially harmful and currently unknown effects
of their long term use, citizens could maintain their auton-
omy and opt into the use of these enhancers, with all
the above considerations [36], if they are able to make
an informed decision on the potential risks involved. So
the discouraged and disincentivised, but widely available
status of cognitive enhancers such as Methylphenidatewould: decrease the capacity for coercion, decrease the
appeal of competitive advantage, provide financing for
medical care of the most disadvantaged in society, and
fund research into treating previously neglected conditions.
This appears a better state of affairs than the status quo of
the unregulated use of Methylphenidate.
We would further propose that medical students and
doctors are a well-suited group to conscientiously opt
into the use of cognitive enhancements for a multitude
of reasons. These include the ideas that: they are more
likely to understand the effects of these cognitive enhancers
and less likely to be swayed by the exaggeration of their
effects by pharmaceutical companies, they would be in a
better position to understand the side effect profile of
these enhancers, as well as the prospective long term
effects, they would be more likely to provide accurate
data during a long term prospective cohort study; they
would be in a better position to access the additional
medical insurance required in this policy; finally, once
the research is conducted and results acquired the doctors
involved in the study would be in a well informed position
to advise public policy and debate on the profile of these
cognitive enhancers.
There are further considerations specific to the indi-
vidual role-players, including the patient, that still need
to be accounted for. Allowing medical students and doctors
free access to Methylphenidate may lead to some conduct-
ing the majority of their theoretical and clinical training
under its influence. Which may distort their ability to
accurately discern their level of competence without the
drug, rendering them dependant on the drug to maintain
confidence in providing adequate patient care [5,37]. This
potential for abuse of Methylphenidate when used for
cognitive enhancement may translate to a need to revise
the scheduling of the drug [14]. Adjusting the dose of
Methylphenidate for cognitive enhancement, marketing
it as a different medication than when it is used for its
traditional purpose and initially scheduling the medication
for cognitive enhancement as a controlled substance, like
morphine, would make moderation of distribution signifi-
cantly easier. This would also greater enable the state
regulating bodies of the medical profession, such as the
Health Professions Council of South Africa, to accurately
monitor the distribution of drugs explicitly for cognitive
enhancement, ameliorating their specific risks for abuse,
self-prescription and other areas of possible exploitation.
Summary
The effects of Methylphenidate as a significant cognitive
enhancer are more subjective than practical and the
existing studies are insufficient to directly answer the
long-term side effect profile of this medication amongst
the healthy. Prospective cohort studies must be prioritised
to make accurate decisions on Methylphenidate’s use for
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tion of Methylphenidate is subject to personal, social
and economic advantage. This unjust distribution has a
large potential for increasing the amount of economic and
social disadvantage within society. Regulatory governmen-
tal policy must seek to remedy this while minimising the
potential for competitive advantage for the enhanced. This
will be achieved by disincentivising citizens from their use;
while discouraging their use by personal taxation, the
requirement of the acquisition of a license; .additional
medical insurance, the participation in a long-term cohort
study on their use; and a further corporate tax to act
against the potential for coercion A public debate on the
use of cognitive enhancement is long overdue and must
be stimulated by new analysis and research. The use of
Methylphenidate for cognitive enhancement has been
shown to be defensible from: a utilitarian perspective in
terms of enhancing personal utility for the potential
good of society; a deontological perspective through
the principle of autonomy as an inviolable right; virtue
ethics where the pursuit of a virtuous life is suggested
to be more achievable with the addition of cognitive
enhancement; a perspective of justice. If long-term re-
search can prove that the risks are negligible and the
outcomes tangible then we would defend the regulated
use of Methylphenidate by the healthy and believe medical
students and doctors represent a good group to initially
implement this policy.
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